Inventiva SA ADR IVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.16
- Day Range
- $3.06–3.28
- 52-Week Range
- $2.40–5.05
- Bid/Ask
- $3.25 / $3.30
- Market Cap
- $169.38 Mil
- Volume/Avg
- 24,741 / 43,039
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.58
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 123
- Website
- https://www.inventivapharma.com
Comparables
Valuation
|
Metric
|
IVA
|
AB
|
AELIS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 1.22 | — |
Price/Book Value | — | — | 9.98 |
Price/Sales | 7.58 | 153.65 | 13.79 |
Price/Cash Flow | — | — | — |
Price/Earnings
IVA
AB
AELIS
Financial Strength
|
Metric
|
IVA
|
AB
|
AELIS
|
|---|---|---|---|
Quick Ratio | 0.85 | 1.39 | 2.29 |
Current Ratio | 0.96 | 1.43 | 2.41 |
Interest Coverage | −20.40 | −6.34 | −38.47 |
Quick Ratio
IVA
AB
AELIS
Profitability
|
Metric
|
IVA
|
AB
|
AELIS
|
|---|---|---|---|
Return on Assets (Normalized) | −125.09% | −62.36% | −13.75% |
Return on Equity (Normalized) | −5,550.40% | — | −26.44% |
Return on Invested Capital (Normalized) | −275.68% | — | −31.64% |
Return on Assets
IVA
AB
AELIS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bkdyqsxs | Wtprs | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dqygfxsdn | Zwjgvmd | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dzxkzqhqv | Ygskcz | $97.8 Bil | |
MRNA
| Moderna Inc | Hspczlx | Grmr | $41.3 Bil | |
ARGX
| argenx SE ADR | Yrlrhpdjn | Fgr | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Wssmmcy | Bgjbg | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jxgthkpz | Ljwgy | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bwmvxdfv | Jwbdjk | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zpyqzkqkxt | Kcqmgm | $12.5 Bil | |
INCY
| Incyte Corp | Lsvllypz | Rwtbrp | $11.6 Bil |